Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Mimedx Group Inc (MDXG)

Mimedx Group Inc (MDXG)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
6.86 -0.30 (-4.19%) 04/10/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 6.86 unch (unch) 16:01 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.74
Day High
7.23
Open 7.23
Previous Close 7.16 7.16
Volume 506,300 506,300
Avg Vol 538,760 538,760
Stochastic %K 18.31% 18.31%
Weighted Alpha -4.57 -4.57
5-Day Change -0.45 (-6.16%) -0.45 (-6.16%)
52-Week Range 5.47 - 10.14 5.47 - 10.14
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,055,141
  • Shares Outstanding, K 147,366
  • Annual Sales, $ 348,880 K
  • Annual Income, $ 42,420 K
  • EBIT $ 60 M
  • EBITDA $ 66 M
  • 60-Month Beta 1.74
  • Price/Sales 2.90
  • Price/Cash Flow 20.71
  • Price/Book 5.22

Options Overview Details

View History
  • Implied Volatility 103.21% ( +4.92%)
  • Historical Volatility 38.00%
  • IV Percentile 79%
  • IV Rank 49.17%
  • IV High 198.15% on 09/18/24
  • IV Low 11.37% on 08/16/24
  • Put/Call Vol Ratio 16.00
  • Today's Volume 17
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 3,458
  • Open Int (30-Day) 2,495

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.06
  • Number of Estimates 1
  • High Estimate 0.06
  • Low Estimate 0.06
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.70 +2.46%
on 04/09/25
Period Open: 7.79
8.20 -16.34%
on 03/12/25
-0.93 (-11.94%)
since 03/10/25
3-Month
6.70 +2.46%
on 04/09/25
Period Open: 8.65
9.36 -26.73%
on 01/21/25
-1.79 (-20.69%)
since 01/10/25
52-Week
5.47 +25.41%
on 10/10/24
Period Open: 6.55
10.14 -32.35%
on 12/10/24
+0.31 (+4.73%)
since 04/10/24

Most Recent Stories

More News
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

MDXG : 6.86 (-4.19%)
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

MDXG : 6.86 (-4.19%)
MiMedx: Q4 Earnings Snapshot

MiMedx: Q4 Earnings Snapshot

MDXG : 6.86 (-4.19%)
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

MDXG : 6.86 (-4.19%)
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26

MDXG : 6.86 (-4.19%)
MiMedx Group, Inc. Files Patent Infringement Lawsuit Against Surgenex, LLC

MiMedx filed a lawsuit against Surgenex for alleged patent infringement of placental allograft products, seeking damages and injunction.Quiver AI SummaryMiMedx Group, Inc. has initiated a lawsuit against...

MDXG : 6.86 (-4.19%)
MIMEDX Files Patent Infringement Lawsuit Against Surgenex

MDXG : 6.86 (-4.19%)
MIMEDX to Participate in Upcoming Investor Conferences

MDXG : 6.86 (-4.19%)
MiMedx Group, Inc. Announces Regulatory Changes Impacting Coverage for Skin Substitute Grafts

Revised LCDs will eliminate coverage for over 200 unproven skin substitutes, promoting clinically validated treatments.Quiver AI SummaryMiMedx Group, Inc. announced that over 200 unproven skin substitute...

MDXG : 6.86 (-4.19%)
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

MDXG : 6.86 (-4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the...

See More

Key Turning Points

3rd Resistance Point 7.64
2nd Resistance Point 7.44
1st Resistance Point 7.15
Last Price 6.86
1st Support Level 6.65
2nd Support Level 6.45
3rd Support Level 6.16

See More

52-Week High 10.14
Fibonacci 61.8% 8.36
Fibonacci 50% 7.81
Fibonacci 38.2% 7.25
Last Price 6.86
52-Week Low 5.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar